| Literature DB >> 25152756 |
Weidong Qian1, Xingjiang Xiong2, Zhuyuan Fang3, Haiting Lu1, Zhensheng Wang1.
Abstract
Myocardial ischemia-reperfusion injury (MIRI) is a common pathological and physiological phenomenon. Tetramethylpyrazine is the extract of the traditional Chinese medicine Chuanxiong, which can exert protective effects on MIRI in multiple ways. This paper reviewed the current research progress and evidence about the cardiovascular effects of tetramethylpyrazine, which included protecting mitochondria and improving energy metabolism, scavenging oxygen free radicals (OFRs) to inhibit lipid peroxidation, attenuating calcium (Ca(2+)) overload and maintaining Ca(2+) homeostasis in cells, inhibiting apoptosis and protecting myocardial cells, interfering with the inflammatory reaction and mitigating cell injury, interfering with cell signaling pathways, and improving function of endothelial cells and protecting myocardial cells. However, further rigorously designed randomized controlled trials are warranted.Entities:
Year: 2014 PMID: 25152756 PMCID: PMC4135172 DOI: 10.1155/2014/107501
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Figure 1Morphology of tetramethylpyrazine.
Figure 2Molecular formula of tetramethylpyrazine.
Protection of mitochondria and improvement of energy metabolism during MIRI.
| Pharmacological action | Methods | Reference |
|---|---|---|
| Protect mitochondria and improve energy metabolism | Reduce myocardial ATP delay ATP breakdown |
Nordlie et al. 2006 [ |
| Protect Na+-K+-ATPase activity |
Wang et al. 2003 [ | |
| Stimulate synthesis of protein and RNA |
Zhu et al. 2010 [ | |
| Maintain the complete structure of biological membranes and myocardial fibers |
Shi et al. 1998 [ | |
| Reduce SDH and CCO deactivation |
Wang et al. 1998 [ | |
| Increase activity of Ca2+-ATPase and Ca2+-Mg2+-ATPase and regulate expression of the Bcl-2 gene |
Wan et al. 2001 [ |
Scavenge OFRs to inhibit lipid peroxidation.
| Pharmacological action | Methods | Reference |
|---|---|---|
| Scavenge OFRs to inhibit lipid peroxidation | Prevent formation of peroxynitrites |
Du et al. 2009 [ |
| Activate SOD and GSH-Px |
Liu et al. 2005 [ | |
| Induction of HO-1 |
Wang et al. 2008 [ | |
| Protect SOD activity |
Chen et al. 2006 [ |
Attenuate calcium overload and maintain cellular calcium homeostasis.
| Pharmacological action | Methods | Reference |
|---|---|---|
| Attenuate Ca2+ overload and maintain cellular Ca2+ homeostasis | Reduce deactivation of K+-Na+-ATP and Ca2+-ATP |
Ruiz-Meana and García-Dorado 2009 [ |
| Reduce level of Fas protein |
Xu 2003 [ | |
| Inhibition of early-after-depolarization |
Zhang et al. 2009 [ |
Inhibition of apoptosis.
| Pharmacological action | Methods | Reference |
|---|---|---|
| Inhibit apoptosis | Stop transmission of LPS signal |
Xie et al. 2004 [ |
| Promote bcl-2 expression, increase the Bcl-2/Bax ratio |
Wan et al. 2004 [ | |
| Attenuate activation of caspase-3 |
Liu and Niu 2011 [ | |
| Inhibit the intensity of Fas/Fas L | Zhang et al. 2009 [ | |
| Activate the JAK2/STAT3 signal pathway |
Zhang et al. 2007 [ |
Interference with the inflammatory reaction.
| Pharmacological action | Methods | Reference |
|---|---|---|
| Interference with the inflammatory reaction | Decrease activity of p38MAPK |
Castaneda et al. 2003 [ |
| Inhibit the expression of E-selectin and P-selectin |
Shang et al. 2008 [ | |
| Inhibit ICAM-1 expression |
Pan and Jin 2008 [ |
Interference with cell signaling pathways.
| Pharmacological action | Methods | Reference |
|---|---|---|
| Interfere cell signal pathway | Activate the PI3K/Akt-eNOS signaling pathway |
Fulton et al. 1999 [ |
| Increase the activity of PKC and Gi/o |
Jiang et al. 2012 [ | |
| Increase expression of HSP70 |
Liang et al. 2001 [ | |
| Increase adiponectin level |
Chen et al. 2007 [ |
Improve function of endothelial cells.
| Pharmacological action | Methods | Reference |
|---|---|---|
| Improve endothelial cell function | Increase the level of NO and decrease the number of endothelial cells |
C. Q. Li and Y. X. Li 2010 [ |
| Increase the level of 6-Keto-PGF1 |
Wang et al. 2001 [ |